Fluvastin therapy affects TAFI concentration in kidney transplant recipients.

Jolanta Malyszko, Jacek S Malyszko, Michal Mysliwiec

Journal: Transplant international : official journal of the European Society for Organ Transplantation 2003;16(1):53-7

PMID: 12545342

Abstract

Thrombin activatable fibrinolysis inhibitor (TAFI) is a glycoprotein, linking coagulation and fibrinolysis. Recently, attention has been drawn to the beneficial effects of statins on haemostasis in kidney patients prone to dyslipidaemia and with a high risk of cardiovascular death. The purpose of this study was to assess whether fluvastatin affects TAFI concentration in renal transplant recipients. We evaluated thrombin-antithrombin (TAT) complexes, prothrombin fragments 1+2, thrombomodulin, plasmin-antiplasmin (PAP) complexes, TAFI, P-selectin, and lipoprotein (a), 1, 2, and 3 months before and after fluvastatin treatment and in normolipaemic kidney transplant recipients and healthy volunteers. Cholesterol and LDL fell significantly as soon as 1 month after treatment had begun and remained lowered during the therapy. TAFI and prothrombin fragments 1+2 decreased significantly after 3 months of fluvastatin administration, whereas P-selectin decreased significantly after 2 months and remained significantly lower after 3 months of this therapy. We can conclude that fluvastatin is an effective hypolipaemic agent that favourably affects haemostasis.

Address: Department of Nephrology and Internal Medicine, Medical Academy Bialystok, Zurawia 14, 15-540 Bialystok, Poland.

DOI: 10.1007/s00147-002-0495-9

Link outs

Free resources

Medical:

https://medlineplus.gov/cholesterolmedicines.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-ASAP1-1

Subscription / membership required

Full Text Sources:

http://link.springer.com/article/10.1007/s00147-00...

MeSH Terms: Adult, Antithrombin III, Carboxypeptidase B2, Fatty Acids, Monounsaturated, Female, Fibrinolysin, Fluvastatin, Hemostasis, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipidemias, Indoles, Kidney Transplantation, Lipids, Male, Middle Aged, P-Selectin, Peptide Fragments, Peptide Hydrolases, Protein Precursors, Prothrombin